Interpreting ReoPro's EPILOG results

Investigators presented final six-month data from the EPILOG trial of Centocor Inc.'s ReoPro GPIIb/IIIa inhibitor in all comers undergoing angioplasty. As reported Sunday at the American Heart Association meeting in

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE